Issued: 22 February 2019, London UK - LSE Announcement
GSK response to SFO Statement
In reference to the announcement issued by the Serious Fraud Office ('SFO') today, GlaxoSmithKline plc (LSE/NYSE: GSK) is pleased that the SFO have closed their investigation and concluded that no further action is required.
About GSK
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information please visit www.gsk.com.
GSK enquiries: | |||
UK Media enquiries: | Simon Steel | +44 (0) 20 8047 5502 | (London) |
Tim Foley | +44 (0) 20 8047 5502 | (London) | |
Analyst/Investor enquiries: | Sarah Elton-Farr | +44 (0) 208 047 5194 | (London) |
Jeff McLaughlin | +1 215 751 7002 | (Philadelphia) |
Cautionary statements regarding forward-looking statements | |
Registered in England & Wales: No. 3888792 | |
Registered Office: 980 Great West Road Brentford, Middlesex TW8 9GS |
Attachments
- Original document
- Permalink
Disclaimer
GSK - GlaxoSmithKline plc published this content on 22 February 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 22 February 2019 11:35:11 UTC